News

Adamas Pharma Announces Submission of ADS-5102 NDA to US FDA as Dyskinesia Treatment in PD Patients

(October 31, 2016) – Adamas Pharmaceuticals, Inc announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for ADS-5102 (amantadine hydrochloride) extended-release capsules, the company’s proprietary lead product candidate, for the potential treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease. Read more

Follow Us Follow us on TwitterFollow us on FacebookInstagram

Sign Up for Email Alerts

By providing your email you agree to receive periodic emails from The Parkinson Alliance.

Please tell us more about yourself:

This month is? (Anti-Spam)

Contact UsTerms Of UsePrivacy Policy

The Parkinson Alliance is a nonprofit, tax-exempt charitable organization under section 501(c)(3) of the Internal Revenue Code. Donations are tax-deductible as allowed by law. Copyright © 2020 The Parkinson Alliance. All rights reserved.